Detection of Sibutramine in weight-loss products in Syrian market

  • 02 Jul 2022
  • Ongoing Research - Pharmacy

Afraa Alnokkari


Post Graduate Studies & Research Council Meeting No. 7, 26/6/2022

Date of Acceptance


Nowadays, obesity has become a challenge in public health due to the increasing trend in its prevalence. Based on the World Health Organization’s (WHO) definition of overweight and obesity, It would increase the risk of developing various chronic diseases such as cancer, diabetes, psychosocial dysfunction, gout, arthritis, and cardiovascular disease. Overall, obesity increases the rate of morbidity and mortality. Considering these health risks as a consequence of obesity, weight loss and treatment of obesity are of high importance. Hence, various methods such as diet, physical activity, pharmacologic strategies, and surgical intervention have been used to lose weight.

All weight loss products must be approved by the Food and Drug Organization and manufactured based on Good Manufacturing Practice (GMP) methods. There is growing concern over the presence of illicit substances, such as CNS stimulants and psychotropic agents in these products that could bring serious adverse effects. Sibutramine, methamphetamine, metformin, and bupropion are the most illicit substances found in weight loss products.

The addition of these medicines to weight loss products may result in many side effects such as dry mouth, hand tremors, hypertension, sleep disturbances, loss of appetite, palpitations, asthma, renal and liver damage, and cardiovascular diseases.